The ASAM Treatment of Opioid Use Disorder Course 8-Hour Online

4.8 (5 votes)

image

8-Hour Online Course for Physicians*

Welcome to The ASAM Treatment of Opioid Use Disorder Course. This course provides 8 hours of education needed for physicians  to receive a waiver to prescribe buprenorphine in an office-based setting. More information on waiver requirements can be found on the SAMHSA website.

To begin the online course, please log-in to your left and locate the box that says, "Module 1" in the "Contents" tab. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

All online modules and quizzes must be completed before you can claim credit for the course. Detailed instructions for completing the  course can be found under the tab titled, "Course Instructions."

After completing the online modules, corresponding quizzes, and applicable evaluations, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

*NPs, PAs, CNMs, CRNAs, and other CNSs are required to complete no less than 24 hours of training. ASAM offers 24 hour packages for free. Click here for more information.

Note: Resident & Fellow ASAM Members (in training) receive complimentary access to the 8-hour online ASAM Treatment of Opioid Use Disorder Course. Click here to become a member. Please note membership approval requires up to two business days.

Key:

Complete
Failed
Available
Locked
Module 1
Begin self-paced component package.
Begin self-paced component package. Click "View Course" to launch the course.
Module 2
Begin self-paced component package.
Begin self-paced component package. Click "View Course" to launch the course.
Module 3
Begin self-paced component package.
Begin self-paced component package. Click "View Course" to launch the course.
Module 4
Begin self-paced component package.
Begin self-paced component package. Click "View Course" to launch the course.
CME Evaluation
15 Questions
15 Questions Fill out the CME evaluation to gain access to your CME certificate.
CME Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available Access your certificate here. Use this certificate to apply for the waiver.

Daniel P. Alford

MD, MPH, FACP, DFASAM

Dr. Daniel P. Alford is an Associate Professor of Medicine, Assistant Dean of CME and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine (ABAM).

He is director of the Clinical Addiction Research and Education Unit medical director of the Office-Based Opioid Treatment (OBOT) program and of the Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program and former program director for the Addiction Medicine Fellowship program at Boston Medical Center (BMC). Since 2001 he has served as the course director of the Chief Resident Immersion Training (CRIT) Program in Addiction Medicine: Improving Clinical and Teaching Skills for Generalists funded by NIDA. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA). In 2011, he was recognized as a Champion of Change by the White House. In 2014 he received the Health Education Award from the American Medical Association.

R. Corey Waller

MD, MS, DFASAM

R. Corey Waller, MD, MS, FACEP, DFASAM, is an addiction, pain and emergency medicine specialist. Dr. Waller earned his bachelor's degree in biology and his master's degree in neuromolecular biology at Southwest Texas State University in San Marcos, Texas. He earned his medical degree at University of Texas Medical School in San Antonio. Dr. Waller completed his emergency medicine residency at Thomas Jefferson University in Philadelphia. He is board certified and fellowship trained in addiction medicine.

Debra Newman

PA-C, MPAS, MPH

Debra R. Newman, PA-C, MPAS, MPH currently serves as treatment provider for First Judicial District Court, Adult Drug Court for Santa Fe and Rio Arriba Counties, New Mexico. She is also working part-time as a contract provider in Chemical Dependency for Kaiser Permanente in Denver, Colorado. Debra has worked in residential treatment as well as out-patient adult psychiatry and addiction medicine. Her passion for addiction medicine began with her association with Project ECHO in 2008. While employed at an FQHC in northern NM in a region historically plagued with the highest per capita heroin death rate in the nation, Debra worked under an addiction medicine psychiatrist and several family practice physicians waivered to prescribe buprenorphine. For over four years, she managed over 200 buprenorphine patients monthly, as the only full-time provider for these patients, while also carrying a caseload of HCV and chronic pain patients. She is currently working with the PA Foundation and NIDA on a grant examining the role of PA’s in drug courts.

Marian Currens

Associate Director, University of Maryland Medical Center Midtown Campus

Learning Objectives:

  1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorder
  2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
  3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
  4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
  5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorder
  6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
  7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorder
  8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
  9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorder
  10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorder
  11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder
  12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies no less than 8 hours of training is necessary for physicians to obtain a waiver to engage in office-based treatment of opioid use disorder using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

For 24-Hour Treatment of Opioid Use Disorder Course issuing AANP CE Credit: Click Here

For 24-Hour Treatment of Opioid Use Disorder Course issuing AAPA Category 1 CME Credit or AMA PRA Category 1 CME Credit: Click Here


This training is divided into two parts of 8 hours and 16 hours. If you have already completed the 8-hour DATA2000 course, you will only need to complete the second part of the 16-hour course.

Legislation
Comprehensive Addiction and Recovery Act (CARA)
ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

HR6 - SUPPORT for Patients and Communities Act
HR6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, added qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives to list of practitioners eligible to prescribe buprenorphine until October 1, 2023. The ASAM Treatment of Opioid Use Disorder Course is available for qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives.

Qualify
To qualify for a waiver, NPs, PAs, CRNAs, CNMs, and CNSs must:

  • Be licensed under state law to prescribe Schedule III, IV, or V medications for pain
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver. 

  1. Providers who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
  2. Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.

ASAM would like to acknowledge the following supporters:

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

Funding for this initiative was made possible (in part) by grant no. 1H79TI026793-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.